JP6449781B2 - 微細小胞の単離方法 - Google Patents
微細小胞の単離方法 Download PDFInfo
- Publication number
- JP6449781B2 JP6449781B2 JP2015551774A JP2015551774A JP6449781B2 JP 6449781 B2 JP6449781 B2 JP 6449781B2 JP 2015551774 A JP2015551774 A JP 2015551774A JP 2015551774 A JP2015551774 A JP 2015551774A JP 6449781 B2 JP6449781 B2 JP 6449781B2
- Authority
- JP
- Japan
- Prior art keywords
- rna
- microvesicles
- plasma
- filter
- buffer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000000034 method Methods 0.000 title claims description 180
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 361
- 210000002381 plasma Anatomy 0.000 claims description 264
- 239000012528 membrane Substances 0.000 claims description 220
- 108020004999 messenger RNA Proteins 0.000 claims description 114
- 102000039446 nucleic acids Human genes 0.000 claims description 111
- 108020004707 nucleic acids Proteins 0.000 claims description 111
- 150000007523 nucleic acids Chemical class 0.000 claims description 111
- 239000002679 microRNA Substances 0.000 claims description 96
- 239000012160 loading buffer Substances 0.000 claims description 94
- 239000012472 biological sample Substances 0.000 claims description 86
- 230000007935 neutral effect Effects 0.000 claims description 77
- 239000004627 regenerated cellulose Substances 0.000 claims description 75
- 210000002700 urine Anatomy 0.000 claims description 26
- 239000012139 lysis buffer Substances 0.000 claims description 24
- 239000011148 porous material Substances 0.000 claims description 20
- 210000001175 cerebrospinal fluid Anatomy 0.000 claims description 19
- 239000003153 chemical reaction reagent Substances 0.000 claims description 18
- 125000001453 quaternary ammonium group Chemical group 0.000 claims description 9
- 210000002966 serum Anatomy 0.000 claims description 9
- 238000004113 cell culture Methods 0.000 claims description 8
- 239000012228 culture supernatant Substances 0.000 claims description 8
- 108091070501 miRNA Proteins 0.000 claims description 8
- 230000014759 maintenance of location Effects 0.000 claims 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 316
- 239000000523 sample Substances 0.000 description 205
- 239000011324 bead Substances 0.000 description 158
- 239000011780 sodium chloride Substances 0.000 description 158
- 238000005199 ultracentrifugation Methods 0.000 description 131
- 238000001914 filtration Methods 0.000 description 119
- 238000002955 isolation Methods 0.000 description 119
- 239000004695 Polyether sulfone Substances 0.000 description 105
- 229920006393 polyether sulfone Polymers 0.000 description 105
- 108700011259 MicroRNAs Proteins 0.000 description 92
- 239000007989 BIS-Tris Propane buffer Substances 0.000 description 87
- HHKZCCWKTZRCCL-UHFFFAOYSA-N bis-tris propane Chemical compound OCC(CO)(CO)NCCCNC(CO)(CO)CO HHKZCCWKTZRCCL-UHFFFAOYSA-N 0.000 description 87
- 239000011534 wash buffer Substances 0.000 description 87
- 239000000872 buffer Substances 0.000 description 82
- 239000010410 layer Substances 0.000 description 78
- 239000006167 equilibration buffer Substances 0.000 description 77
- 238000000605 extraction Methods 0.000 description 72
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 68
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 68
- 238000003757 reverse transcription PCR Methods 0.000 description 66
- 108090000623 proteins and genes Proteins 0.000 description 60
- 238000011067 equilibration Methods 0.000 description 55
- 239000000706 filtrate Substances 0.000 description 52
- 108091091807 let-7a stem-loop Proteins 0.000 description 51
- 108091057746 let-7a-4 stem-loop Proteins 0.000 description 51
- 108091028376 let-7a-5 stem-loop Proteins 0.000 description 51
- 108091024393 let-7a-6 stem-loop Proteins 0.000 description 51
- 108091091174 let-7a-7 stem-loop Proteins 0.000 description 51
- 239000002245 particle Substances 0.000 description 45
- 238000011084 recovery Methods 0.000 description 39
- 238000004458 analytical method Methods 0.000 description 38
- 238000009826 distribution Methods 0.000 description 38
- 108091032955 Bacterial small RNA Proteins 0.000 description 35
- 238000002123 RNA extraction Methods 0.000 description 35
- 238000011529 RT qPCR Methods 0.000 description 35
- 108091027943 miR-16 stem-loop Proteins 0.000 description 35
- 238000012360 testing method Methods 0.000 description 35
- 108020004414 DNA Proteins 0.000 description 33
- 230000003321 amplification Effects 0.000 description 33
- 238000003199 nucleic acid amplification method Methods 0.000 description 33
- 239000000203 mixture Substances 0.000 description 32
- 239000007983 Tris buffer Substances 0.000 description 31
- 238000010804 cDNA synthesis Methods 0.000 description 31
- 230000009089 cytolysis Effects 0.000 description 30
- 230000014509 gene expression Effects 0.000 description 30
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 30
- 108020004635 Complementary DNA Proteins 0.000 description 29
- 102100029098 Hypoxanthine-guanine phosphoribosyltransferase Human genes 0.000 description 29
- 239000002299 complementary DNA Substances 0.000 description 29
- 210000004027 cell Anatomy 0.000 description 28
- 238000009987 spinning Methods 0.000 description 28
- 230000027455 binding Effects 0.000 description 26
- 238000003762 quantitative reverse transcription PCR Methods 0.000 description 26
- 101000896557 Homo sapiens Eukaryotic translation initiation factor 3 subunit B Proteins 0.000 description 25
- 101000988834 Homo sapiens Hypoxanthine-guanine phosphoribosyltransferase Proteins 0.000 description 25
- 239000006228 supernatant Substances 0.000 description 25
- 101000984753 Homo sapiens Serine/threonine-protein kinase B-raf Proteins 0.000 description 24
- 102100027103 Serine/threonine-protein kinase B-raf Human genes 0.000 description 24
- 238000001514 detection method Methods 0.000 description 24
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 24
- 108091027963 non-coding RNA Proteins 0.000 description 23
- 102000042567 non-coding RNA Human genes 0.000 description 23
- 230000002441 reversible effect Effects 0.000 description 23
- 206010028980 Neoplasm Diseases 0.000 description 22
- 238000005119 centrifugation Methods 0.000 description 22
- 239000003161 ribonuclease inhibitor Substances 0.000 description 22
- 238000006243 chemical reaction Methods 0.000 description 21
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 20
- 238000002474 experimental method Methods 0.000 description 20
- 238000000967 suction filtration Methods 0.000 description 20
- 239000004593 Epoxy Substances 0.000 description 19
- 108091046841 MiR-150 Proteins 0.000 description 19
- 238000011156 evaluation Methods 0.000 description 19
- 102100027314 Beta-2-microglobulin Human genes 0.000 description 18
- 101000937544 Homo sapiens Beta-2-microglobulin Proteins 0.000 description 18
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical group O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 18
- 102100026031 Beta-glucuronidase Human genes 0.000 description 17
- 101000933465 Homo sapiens Beta-glucuronidase Proteins 0.000 description 17
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 17
- 230000035772 mutation Effects 0.000 description 17
- 238000000746 purification Methods 0.000 description 17
- 238000004448 titration Methods 0.000 description 17
- 239000008188 pellet Substances 0.000 description 16
- 210000001124 body fluid Anatomy 0.000 description 15
- 238000010828 elution Methods 0.000 description 15
- 230000001965 increasing effect Effects 0.000 description 15
- 102000004169 proteins and genes Human genes 0.000 description 15
- 150000003839 salts Chemical class 0.000 description 15
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 14
- 239000010839 body fluid Substances 0.000 description 14
- 201000010099 disease Diseases 0.000 description 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 14
- 102100039540 Exocyst complex component 7 Human genes 0.000 description 13
- 101000813489 Homo sapiens Exocyst complex component 7 Proteins 0.000 description 13
- 239000012148 binding buffer Substances 0.000 description 13
- 239000012530 fluid Substances 0.000 description 13
- 102200055464 rs113488022 Human genes 0.000 description 13
- 150000001412 amines Chemical class 0.000 description 12
- 230000000694 effects Effects 0.000 description 12
- 239000000463 material Substances 0.000 description 12
- 239000007788 liquid Substances 0.000 description 11
- 239000000090 biomarker Substances 0.000 description 10
- OWMVSZAMULFTJU-UHFFFAOYSA-N bis-tris Chemical compound OCCN(CCO)C(CO)(CO)CO OWMVSZAMULFTJU-UHFFFAOYSA-N 0.000 description 10
- 238000010805 cDNA synthesis kit Methods 0.000 description 10
- 201000011510 cancer Diseases 0.000 description 10
- 238000002360 preparation method Methods 0.000 description 10
- 238000000108 ultra-filtration Methods 0.000 description 10
- 150000001450 anions Chemical class 0.000 description 9
- 150000001768 cations Chemical class 0.000 description 9
- 230000001143 conditioned effect Effects 0.000 description 9
- 238000003745 diagnosis Methods 0.000 description 9
- 238000011534 incubation Methods 0.000 description 9
- 239000000377 silicon dioxide Substances 0.000 description 9
- 238000011282 treatment Methods 0.000 description 9
- 238000005406 washing Methods 0.000 description 9
- 241000713887 Human endogenous retrovirus Species 0.000 description 8
- 239000003795 chemical substances by application Substances 0.000 description 8
- 238000004090 dissolution Methods 0.000 description 8
- 230000036541 health Effects 0.000 description 8
- 230000005764 inhibitory process Effects 0.000 description 8
- 238000011068 loading method Methods 0.000 description 8
- 238000012544 monitoring process Methods 0.000 description 8
- 239000004677 Nylon Substances 0.000 description 7
- 102000035195 Peptidases Human genes 0.000 description 7
- 108091005804 Peptidases Proteins 0.000 description 7
- 239000004365 Protease Substances 0.000 description 7
- -1 RNA Chemical class 0.000 description 7
- 241000700605 Viruses Species 0.000 description 7
- 239000000427 antigen Substances 0.000 description 7
- 108091007433 antigens Proteins 0.000 description 7
- 102000036639 antigens Human genes 0.000 description 7
- 238000003556 assay Methods 0.000 description 7
- 239000012141 concentrate Substances 0.000 description 7
- 238000010494 dissociation reaction Methods 0.000 description 7
- 230000005593 dissociations Effects 0.000 description 7
- 238000003633 gene expression assay Methods 0.000 description 7
- 229920001778 nylon Polymers 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 238000010839 reverse transcription Methods 0.000 description 7
- 239000001488 sodium phosphate Substances 0.000 description 7
- 229910000162 sodium phosphate Inorganic materials 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 239000004094 surface-active agent Substances 0.000 description 7
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 7
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 229920002678 cellulose Polymers 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 239000000306 component Substances 0.000 description 6
- 230000001419 dependent effect Effects 0.000 description 6
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 6
- 238000010790 dilution Methods 0.000 description 6
- 239000012895 dilution Substances 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 238000005191 phase separation Methods 0.000 description 6
- 238000003753 real-time PCR Methods 0.000 description 6
- 239000011347 resin Substances 0.000 description 6
- 229920005989 resin Polymers 0.000 description 6
- 239000013017 sartobind Substances 0.000 description 6
- 239000002356 single layer Substances 0.000 description 6
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 6
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 5
- 102000006382 Ribonucleases Human genes 0.000 description 5
- 108010083644 Ribonucleases Proteins 0.000 description 5
- 230000005856 abnormality Effects 0.000 description 5
- 238000005349 anion exchange Methods 0.000 description 5
- 238000010586 diagram Methods 0.000 description 5
- 210000001808 exosome Anatomy 0.000 description 5
- 125000000524 functional group Chemical group 0.000 description 5
- 239000002773 nucleotide Substances 0.000 description 5
- 125000003729 nucleotide group Chemical group 0.000 description 5
- 238000011045 prefiltration Methods 0.000 description 5
- 238000012545 processing Methods 0.000 description 5
- 238000004393 prognosis Methods 0.000 description 5
- 241000701161 unidentified adenovirus Species 0.000 description 5
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 4
- 101710132601 Capsid protein Proteins 0.000 description 4
- 101710094648 Coat protein Proteins 0.000 description 4
- 241001534160 Escherichia virus Qbeta Species 0.000 description 4
- 108010091358 Hypoxanthine Phosphoribosyltransferase Proteins 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- 101710125418 Major capsid protein Proteins 0.000 description 4
- 101710141454 Nucleoprotein Proteins 0.000 description 4
- 101710083689 Probable capsid protein Proteins 0.000 description 4
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 4
- 230000002378 acidificating effect Effects 0.000 description 4
- 239000003729 cation exchange resin Substances 0.000 description 4
- 239000000356 contaminant Substances 0.000 description 4
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 4
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 4
- 238000010195 expression analysis Methods 0.000 description 4
- 239000003365 glass fiber Substances 0.000 description 4
- 238000005342 ion exchange Methods 0.000 description 4
- 239000006166 lysate Substances 0.000 description 4
- 201000001441 melanoma Diseases 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 4
- 108020004418 ribosomal RNA Proteins 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical group [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 4
- 102000016911 Deoxyribonucleases Human genes 0.000 description 3
- 108010053770 Deoxyribonucleases Proteins 0.000 description 3
- 102100021181 Golgi phosphoprotein 3 Human genes 0.000 description 3
- 101001046870 Homo sapiens Hypoxia-inducible factor 1-alpha Proteins 0.000 description 3
- 102100022875 Hypoxia-inducible factor 1-alpha Human genes 0.000 description 3
- 229910019142 PO4 Inorganic materials 0.000 description 3
- 229920012266 Poly(ether sulfone) PES Polymers 0.000 description 3
- 108020004566 Transfer RNA Proteins 0.000 description 3
- 239000013504 Triton X-100 Substances 0.000 description 3
- 229920004890 Triton X-100 Polymers 0.000 description 3
- 238000001042 affinity chromatography Methods 0.000 description 3
- 239000003957 anion exchange resin Substances 0.000 description 3
- 125000000129 anionic group Chemical group 0.000 description 3
- 239000007853 buffer solution Substances 0.000 description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
- 125000002091 cationic group Chemical group 0.000 description 3
- 238000001085 differential centrifugation Methods 0.000 description 3
- 239000003480 eluent Substances 0.000 description 3
- 239000003623 enhancer Substances 0.000 description 3
- 238000005227 gel permeation chromatography Methods 0.000 description 3
- 230000002068 genetic effect Effects 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 230000002934 lysing effect Effects 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- ZIYVHBGGAOATLY-UHFFFAOYSA-N methylmalonic acid Chemical compound OC(=O)C(C)C(O)=O ZIYVHBGGAOATLY-UHFFFAOYSA-N 0.000 description 3
- 238000003253 miRNA assay Methods 0.000 description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 3
- 239000010452 phosphate Substances 0.000 description 3
- 229910000160 potassium phosphate Inorganic materials 0.000 description 3
- 235000011009 potassium phosphates Nutrition 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 238000011002 quantification Methods 0.000 description 3
- 230000010076 replication Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 238000010561 standard procedure Methods 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 230000036962 time dependent Effects 0.000 description 3
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 2
- 108091023037 Aptamer Proteins 0.000 description 2
- 206010003445 Ascites Diseases 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- 238000007400 DNA extraction Methods 0.000 description 2
- 229920002307 Dextran Polymers 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 102000018651 Epithelial Cell Adhesion Molecule Human genes 0.000 description 2
- 108010066687 Epithelial Cell Adhesion Molecule Proteins 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 102000005431 Molecular Chaperones Human genes 0.000 description 2
- 108010006519 Molecular Chaperones Proteins 0.000 description 2
- 108020002230 Pancreatic Ribonuclease Proteins 0.000 description 2
- 102000005891 Pancreatic ribonuclease Human genes 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- 206010036790 Productive cough Diseases 0.000 description 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
- 239000013614 RNA sample Substances 0.000 description 2
- 238000010240 RT-PCR analysis Methods 0.000 description 2
- 108020004511 Recombinant DNA Proteins 0.000 description 2
- 241000283984 Rodentia Species 0.000 description 2
- 108020004459 Small interfering RNA Proteins 0.000 description 2
- MZVQCMJNVPIDEA-UHFFFAOYSA-N [CH2]CN(CC)CC Chemical group [CH2]CN(CC)CC MZVQCMJNVPIDEA-UHFFFAOYSA-N 0.000 description 2
- 210000004381 amniotic fluid Anatomy 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 210000000601 blood cell Anatomy 0.000 description 2
- 238000011088 calibration curve Methods 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 239000013522 chelant Substances 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 210000002726 cyst fluid Anatomy 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 238000002270 exclusion chromatography Methods 0.000 description 2
- 125000002485 formyl group Chemical class [H]C(*)=O 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 239000003014 ion exchange membrane Substances 0.000 description 2
- 210000002751 lymph Anatomy 0.000 description 2
- 238000002826 magnetic-activated cell sorting Methods 0.000 description 2
- 230000005389 magnetism Effects 0.000 description 2
- 230000003211 malignant effect Effects 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 231100000150 mutagenicity / genotoxicity testing Toxicity 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 239000013610 patient sample Substances 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 210000004910 pleural fluid Anatomy 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 210000003705 ribosome Anatomy 0.000 description 2
- 210000003296 saliva Anatomy 0.000 description 2
- 238000001878 scanning electron micrograph Methods 0.000 description 2
- 210000000582 semen Anatomy 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 210000003802 sputum Anatomy 0.000 description 2
- 208000024794 sputum Diseases 0.000 description 2
- 239000013595 supernatant sample Substances 0.000 description 2
- 210000001138 tear Anatomy 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 230000002485 urinary effect Effects 0.000 description 2
- 210000001635 urinary tract Anatomy 0.000 description 2
- UMCMPZBLKLEWAF-BCTGSCMUSA-N 3-[(3-cholamidopropyl)dimethylammonio]propane-1-sulfonate Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCC[N+](C)(C)CCCS([O-])(=O)=O)C)[C@@]2(C)[C@@H](O)C1 UMCMPZBLKLEWAF-BCTGSCMUSA-N 0.000 description 1
- GUQQBLRVXOUDTN-XOHPMCGNSA-N 3-[dimethyl-[3-[[(4r)-4-[(3r,5s,7r,8r,9s,10s,12s,13r,14s,17r)-3,7,12-trihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]pentanoyl]amino]propyl]azaniumyl]-2-hydroxypropane-1-sulfonate Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCC[N+](C)(C)CC(O)CS([O-])(=O)=O)C)[C@@]2(C)[C@@H](O)C1 GUQQBLRVXOUDTN-XOHPMCGNSA-N 0.000 description 1
- 101710159080 Aconitate hydratase A Proteins 0.000 description 1
- 101710159078 Aconitate hydratase B Proteins 0.000 description 1
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- GUBGYTABKSRVRQ-WFVLMXAXSA-N DEAE-cellulose Chemical compound OC1C(O)C(O)C(CO)O[C@H]1O[C@@H]1C(CO)OC(O)C(O)C1O GUBGYTABKSRVRQ-WFVLMXAXSA-N 0.000 description 1
- 238000007399 DNA isolation Methods 0.000 description 1
- 108010067770 Endopeptidase K Proteins 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 108700039887 Essential Genes Proteins 0.000 description 1
- 101710145505 Fiber protein Proteins 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 description 1
- 108091069019 Homo sapiens miR-124-1 stem-loop Proteins 0.000 description 1
- 108091069008 Homo sapiens miR-124-2 stem-loop Proteins 0.000 description 1
- 108091069007 Homo sapiens miR-124-3 stem-loop Proteins 0.000 description 1
- 108091068993 Homo sapiens miR-142 stem-loop Proteins 0.000 description 1
- 238000009015 Human TaqMan MicroRNA Assay kit Methods 0.000 description 1
- RAXXELZNTBOGNW-UHFFFAOYSA-O Imidazolium Chemical compound C1=C[NH+]=CN1 RAXXELZNTBOGNW-UHFFFAOYSA-O 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 101150105104 Kras gene Proteins 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 241000714210 Leviviridae Species 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 208000000172 Medulloblastoma Diseases 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 108020005196 Mitochondrial DNA Proteins 0.000 description 1
- 108010085220 Multiprotein Complexes Proteins 0.000 description 1
- 102000007474 Multiprotein Complexes Human genes 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 108020004485 Nonsense Codon Proteins 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 101710093543 Probable non-specific lipid-transfer protein Proteins 0.000 description 1
- 238000010802 RNA extraction kit Methods 0.000 description 1
- 102000044126 RNA-Binding Proteins Human genes 0.000 description 1
- 230000004570 RNA-binding Effects 0.000 description 1
- 101710105008 RNA-binding protein Proteins 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 102000004389 Ribonucleoproteins Human genes 0.000 description 1
- 108010081734 Ribonucleoproteins Proteins 0.000 description 1
- 229930182475 S-glycoside Natural products 0.000 description 1
- 208000003837 Second Primary Neoplasms Diseases 0.000 description 1
- 239000012506 Sephacryl® Substances 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 239000012505 Superdex™ Substances 0.000 description 1
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 description 1
- 108700025716 Tumor Suppressor Genes Proteins 0.000 description 1
- 102000044209 Tumor Suppressor Genes Human genes 0.000 description 1
- 108010067390 Viral Proteins Proteins 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 125000003172 aldehyde group Chemical group 0.000 description 1
- 238000007844 allele-specific PCR Methods 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 238000011888 autopsy Methods 0.000 description 1
- 239000013060 biological fluid Substances 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 239000012503 blood component Substances 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 235000011089 carbon dioxide Nutrition 0.000 description 1
- 230000034303 cell budding Effects 0.000 description 1
- 210000002583 cell-derived microparticle Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 235000013330 chicken meat Nutrition 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000008711 chromosomal rearrangement Effects 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 230000001332 colony forming effect Effects 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 238000005138 cryopreservation Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 125000001664 diethylamino group Chemical group [H]C([H])([H])C([H])([H])N(*)C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 239000012149 elution buffer Substances 0.000 description 1
- 238000012869 ethanol precipitation Methods 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 230000028023 exocytosis Effects 0.000 description 1
- 210000003918 fraction a Anatomy 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 230000005861 gene abnormality Effects 0.000 description 1
- 208000005017 glioblastoma Diseases 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 239000012510 hollow fiber Substances 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000009413 insulation Methods 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 210000004880 lymph fluid Anatomy 0.000 description 1
- 230000001926 lymphatic effect Effects 0.000 description 1
- 230000002101 lytic effect Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 108091034121 miR-92a stem-loop Proteins 0.000 description 1
- 108091041519 miR-92a-3 stem-loop Proteins 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 239000012982 microporous membrane Substances 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 238000001823 molecular biology technique Methods 0.000 description 1
- 229920000344 molecularly imprinted polymer Polymers 0.000 description 1
- 210000002487 multivesicular body Anatomy 0.000 description 1
- 210000003739 neck Anatomy 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 210000002445 nipple Anatomy 0.000 description 1
- 210000000019 nipple aspirate fluid Anatomy 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 238000007826 nucleic acid assay Methods 0.000 description 1
- HEGSGKPQLMEBJL-RKQHYHRCSA-N octyl beta-D-glucopyranoside Chemical compound CCCCCCCCO[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HEGSGKPQLMEBJL-RKQHYHRCSA-N 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 210000003463 organelle Anatomy 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 239000006174 pH buffer Substances 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 238000000710 polymer precipitation Methods 0.000 description 1
- 102000054765 polymorphisms of proteins Human genes 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 238000011085 pressure filtration Methods 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000009145 protein modification Effects 0.000 description 1
- 239000013014 purified material Substances 0.000 description 1
- 238000004451 qualitative analysis Methods 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 238000012204 single target assay Methods 0.000 description 1
- 238000001542 size-exclusion chromatography Methods 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000012799 strong cation exchange Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 125000000542 sulfonic acid group Chemical group 0.000 description 1
- 239000012134 supernatant fraction Substances 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 230000009452 underexpressoin Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1003—Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor
- C12N15/1017—Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor by filtration, e.g. using filters, frits, membranes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1003—Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor
- C12N15/1006—Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor by means of a solid support carrier, e.g. particles, polymers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6806—Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Analytical Chemistry (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361748575P | 2013-01-03 | 2013-01-03 | |
| US61/748,575 | 2013-01-03 | ||
| PCT/US2014/010173 WO2014107571A1 (en) | 2013-01-03 | 2014-01-03 | Methods for isolating microvesicles |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016502862A JP2016502862A (ja) | 2016-02-01 |
| JP2016502862A5 JP2016502862A5 (enExample) | 2018-06-14 |
| JP6449781B2 true JP6449781B2 (ja) | 2019-01-09 |
Family
ID=51062472
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015551774A Active JP6449781B2 (ja) | 2013-01-03 | 2014-01-03 | 微細小胞の単離方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US20150353920A1 (enExample) |
| EP (2) | EP2941629B1 (enExample) |
| JP (1) | JP6449781B2 (enExample) |
| CN (2) | CN110106229B (enExample) |
| AU (2) | AU2014203987B2 (enExample) |
| BR (1) | BR112015016136A2 (enExample) |
| CA (1) | CA2897207C (enExample) |
| IL (2) | IL239786B (enExample) |
| MX (2) | MX392552B (enExample) |
| WO (1) | WO2014107571A1 (enExample) |
Families Citing this family (57)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2012253366A1 (en) * | 2011-05-11 | 2014-01-09 | Exosome Diagnostics, Inc. | Nucleic acid extraction from heterogeneous biological materials |
| ES2708561T3 (es) | 2013-03-14 | 2019-04-10 | Translate Bio Inc | Métodos para la purificación de ARN mensajero |
| US20170165334A1 (en) * | 2015-12-11 | 2017-06-15 | Tianxin Wang | Methods to Treat Diseases with Protein, Peptide, Antigen Modification and Hemopurification |
| US11268085B2 (en) | 2014-05-27 | 2022-03-08 | Exosome Diagnostics, Inc. | Methods for isolating microvesicles and extracting nucleic acids from biological samples |
| AU2015287763B2 (en) | 2014-07-09 | 2019-08-08 | Exosome Diagnostics, Inc. | Methods for isolating microvesicles and extracting nucleic acids from biological samples |
| WO2016007951A1 (en) * | 2014-07-11 | 2016-01-14 | KARNAKIS, Jennifer A. | Compositions and methods for detecting rare sequence variants in nucleic acid sequencing |
| CA2965500A1 (en) | 2014-10-24 | 2016-04-28 | Abbott Molecular Inc. | Enrichment of small nucleic acids |
| EP3112474A1 (en) | 2015-06-29 | 2017-01-04 | Evonik Degussa GmbH | Method of detecting avian necrotic enteritis |
| WO2017062901A2 (en) * | 2015-10-07 | 2017-04-13 | Tymora Analytical Operations Llc | Methods to isolate extracellular vesicles in biofluids for biomarker discovery and disease diagnosis |
| EP3443117A1 (en) | 2016-04-15 | 2019-02-20 | Exosome Diagnostics, Inc. | Plasma-based detection of anaplastic lymphoma kinase (alk) nucleic acids and alk fusion transcripts and uses thereof in diagnosis and treatment of cancer |
| CN105716923A (zh) * | 2016-04-21 | 2016-06-29 | 华南理工大学 | 一种聚合物囊泡扫描电镜样品的制备方法 |
| ES2908932T3 (es) | 2016-05-05 | 2022-05-04 | Exosome Diagnostics Inc | Perfilado de ácidos nucleicos de microvesícula y usos del mismo como características distintivas en diagnóstico de rechazo de trasplante renal |
| US10808240B2 (en) | 2016-05-13 | 2020-10-20 | Exosome Diagnostics, Inc. | Automated and manual methods for isolation of extracellular vesicles and co-isolation of cell-free DNA from biofluids |
| WO2018070479A1 (ja) * | 2016-10-13 | 2018-04-19 | 合同会社みらか中央研究所 | 細胞外小胞の回収方法 |
| WO2018076018A1 (en) | 2016-10-21 | 2018-04-26 | Exosome Diagnostics, Inc. | Sequencing and analysis of exosome associated nucleic acids |
| CA3044056A1 (en) | 2016-11-30 | 2018-06-07 | Exosome Diagnostics, Inc. | Methods and compositions to detect mutations in plasma using exosomal rna and cell free dna from non-small cell lung cancer patients |
| KR20190100174A (ko) * | 2016-12-23 | 2019-08-28 | 엑소팜 리미티드 | 미세소포 및 엑소좀의 정제 또는 단리를 위한 방법 및 조성물 |
| WO2018126278A2 (en) | 2017-01-02 | 2018-07-05 | Exosome Diagnostics, Inc. | Methods to distinguish rna and dna in a combined preparation |
| KR101875594B1 (ko) * | 2017-01-13 | 2018-07-06 | ㈜로제타엑소좀 | 금속을 이용한 세포밖 소포체의 분리 방법 |
| MY201961A (en) | 2017-05-12 | 2024-03-27 | Evonik Operations Gmbh | Method for detecting c. perfringens induced diseases in animals |
| EP3635139A1 (en) | 2017-05-17 | 2020-04-15 | Exosome Diagnostics, Inc. | Microvesicle nucleic acids and/or proteins and uses thereof as markers of renal transplant rejection |
| CN107271655A (zh) * | 2017-05-18 | 2017-10-20 | 成都中医药大学附属医院 | 一种检测尿外泌体荷载miRNAs的试剂盒和方法 |
| US11390864B2 (en) * | 2017-07-12 | 2022-07-19 | Illumina, Inc. | Nucleic acid extraction materials, systems, and methods |
| EP3652315A4 (en) | 2017-07-12 | 2021-09-01 | Exosome Diagnostics, Inc. | METHODS FOR ISOLATION AND ENRICHMENT OF EXTRACELLULAR VESICLE POPULATIONS DERIVED FROM BIOFLUIDS, AND ASSOCIATED METHODS OF USE |
| WO2019018537A1 (en) * | 2017-07-18 | 2019-01-24 | Exosome Diagnostics, Inc. | NUCLEIC ACID SEQUENCING ASSOCIATED WITH EXOSOMAL ISOLATION IN PATIENTS WITH MULTIPLE GLIOBLASTOMA |
| CN111148828A (zh) * | 2017-07-26 | 2020-05-12 | 罗塞塔外排体株式会社 | 利用阳离子分离细胞外囊泡的方法 |
| US11260347B2 (en) * | 2017-12-26 | 2022-03-01 | Limited Liability Company “Prostagnost” | Method and device for separating extracellular vesicles from biological liquids with the aid of cascade ultrafiltration |
| EP3759495A1 (en) | 2018-03-02 | 2021-01-06 | Evonik Operations GmbH | In vitro method for detecting intestinal barrier failure in animals |
| WO2019236853A1 (en) | 2018-06-06 | 2019-12-12 | Exosome Diagnostics, Inc. | Methods for developing urine biomarkers and for detecting bladder cancer |
| EP3807616A4 (en) | 2018-06-18 | 2022-03-23 | Exopharm Limited | METHODS AND COMPOSITIONS FOR PURIFICATION OR ISOLATION OF MICROVESICLES AND EXOSOMES |
| CN108841777A (zh) * | 2018-06-22 | 2018-11-20 | 北京恩泽康泰生物科技有限公司 | 基于静电吸附的胞外囊泡及其内含物的提取方法及装置 |
| US20210239685A1 (en) * | 2018-06-27 | 2021-08-05 | The Trustees Of Indiana University | Methods of analyzing dna in urine |
| US10955379B2 (en) | 2018-09-27 | 2021-03-23 | Taiwan Semiconductor Manufacturing Co., Ltd. | Differential sensing with BioFET sensors |
| CN109337859A (zh) * | 2018-10-08 | 2019-02-15 | 南昌大学 | 一种分离细胞表面囊泡的方法 |
| JP7426725B2 (ja) * | 2018-10-30 | 2024-02-02 | Ｃｒａｉｆ株式会社 | 細胞外小胞を捕捉するために用いられるデバイス、細胞外小胞の保存方法および移送方法 |
| WO2020106853A1 (en) | 2018-11-20 | 2020-05-28 | Exosome Diagnostics, Inc. | Compositions and methods for internal controls of microvesicle isolations |
| JP2020092688A (ja) * | 2018-12-12 | 2020-06-18 | 国立大学法人東海国立大学機構 | マイクロｒｎａを含む体液抽出物 |
| WO2020120376A1 (en) | 2018-12-14 | 2020-06-18 | Evonik Operations Gmbh | In vitro method for detecting avian intestinal dysbiosis |
| EP3931351B1 (en) | 2019-03-01 | 2024-09-11 | Mercy Bioanalytics, Inc. | Method for target entity detection using ligase |
| EP3941607A1 (en) | 2019-03-21 | 2022-01-26 | Codiak BioSciences, Inc. | Process for preparing extracellular vesicles |
| CN112048462B (zh) * | 2019-06-05 | 2022-08-23 | 北京丰特云基科技发展有限公司 | 一种基于阴离子多聚物修饰基质的细胞外囊泡分离富集方法 |
| EP4031865A2 (en) | 2019-09-18 | 2022-07-27 | Exosome Diagnostics, Inc. | Compositions, methods, and kits for the isolation of extracellular vesicles |
| US10984211B1 (en) | 2019-10-18 | 2021-04-20 | Taiwan Semiconductor Manufacturing Co., Ltd. | Semiconductor device with bioFET and biometric sensors |
| EP4077660A1 (en) * | 2019-12-16 | 2022-10-26 | QIAGEN GmbH | Method for enriching vesicular rna |
| EP4077659A1 (en) | 2019-12-16 | 2022-10-26 | QIAGEN GmbH | Enrichment method |
| JP7425403B2 (ja) * | 2020-02-17 | 2024-01-31 | 株式会社Ｊｖｃケンウッド | 生体試料分析方法 |
| CN113495029A (zh) * | 2020-04-01 | 2021-10-12 | 杨昆德 | 用于分离欲求物质的装置和方法 |
| WO2021215878A1 (ko) * | 2020-04-24 | 2021-10-28 | 고려대학교 산학협력단 | 미세소포체 분리방법 및 미세소포체 분리장치 |
| US20230203587A1 (en) | 2020-05-29 | 2023-06-29 | Exosome Diagnostics, Inc. | Use of microvesicle signature for the diagnosis and treatment of kidney transplant rejection |
| WO2022066934A2 (en) * | 2020-09-23 | 2022-03-31 | Codiak Biosciences, Inc. | Process for preparing extracellular vesicles |
| CN112391382B (zh) * | 2020-12-07 | 2022-10-11 | 湖北盛齐安生物科技股份有限公司 | 一种快速提取囊泡dna的方法 |
| JP7773765B2 (ja) * | 2020-12-18 | 2025-11-20 | 国立研究開発法人産業技術総合研究所 | 回収用キットおよび核酸含有溶液の調製方法 |
| US20250075258A1 (en) | 2021-07-16 | 2025-03-06 | Exosome Diagnostics, Inc. | Methods of detecting sjogren's syndrome using salivary exosomes |
| AU2023221644A1 (en) | 2022-02-18 | 2024-09-12 | Bio-Techne Corporation | Use of microvesicle signatures in the identification and treatment of renal disorders |
| WO2024054572A1 (en) | 2022-09-07 | 2024-03-14 | Exosome Diagnostics, Inc. | Methods of detecting sjögren's syndrome using salivary exosomes |
| WO2025057787A1 (ja) * | 2023-09-14 | 2025-03-20 | 東洋紡株式会社 | 細胞外小胞の製造方法 |
| CN117487739B (zh) * | 2023-10-30 | 2024-10-01 | 深圳市茵冠生物科技有限公司 | 一种大规模纯化293细胞外泌体的方法 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4935342A (en) * | 1986-12-01 | 1990-06-19 | Syngene, Inc. | Method of isolating and purifying nucleic acids from biological samples |
| US5438128A (en) * | 1992-02-07 | 1995-08-01 | Millipore Corporation | Method for rapid purifiction of nucleic acids using layered ion-exchange membranes |
| US5639606A (en) | 1993-04-06 | 1997-06-17 | The University Of Rochester | Method for quantitative measurement of gene expression using multiplex competitive reverse transcriptase-polymerase chain reaction |
| FR2788780B1 (fr) | 1999-01-27 | 2001-03-30 | Ap Cells Inc | Procede de preparation de vesicules membranaires |
| GB9927320D0 (en) | 1999-11-18 | 2000-01-12 | Chiron Spa | Exosome separation |
| US6812023B1 (en) | 2000-04-27 | 2004-11-02 | Anosys, Inc. | Methods of producing membrane vesicles |
| JP2004105009A (ja) * | 2002-09-13 | 2004-04-08 | Dojindo Laboratories | テトラフェニルホウ素化合物から成る核酸分離用試薬とそれを用いる核酸分離方法 |
| EP2245199B1 (en) | 2008-02-01 | 2013-11-13 | The General Hospital Corporation | Use of microvesicles in diagnosis, prognosis and treatment of medical diseases and conditions |
| WO2010065765A2 (en) * | 2008-12-04 | 2010-06-10 | Aethlon Medical, Inc. | Affinity capture of circulating biomarkers |
| WO2010141862A2 (en) * | 2009-06-05 | 2010-12-09 | Mayo Foundation For Medical Education And Research | Methods and materials for isolating exosomes |
| US20120177574A1 (en) * | 2009-07-01 | 2012-07-12 | Aeon Medix Inc. | Microvesicles derived from nucleated, mammalian cells and use thereof |
| WO2012006476A2 (en) * | 2010-07-07 | 2012-01-12 | Aethlon Medical, Inc. | Methods and compositions for quantifying exosomes |
| WO2012064993A1 (en) * | 2010-11-10 | 2012-05-18 | Exosome Diagnosties, Inc. | Method for isolation of nucleic acid containing particles and extraction of nucleic acids therefrom |
| SG190450A1 (en) * | 2010-12-20 | 2013-06-28 | Agency Science Tech & Res | Method of purifying exosomes |
| BR112013032232A2 (pt) * | 2011-06-16 | 2016-09-20 | Caris Life Sciences Switzerland Holdings S A R L | método de caracterização de câncer através do uso de biomarcador de ácido nucleico |
-
2014
- 2014-01-03 MX MX2019007742A patent/MX392552B/es unknown
- 2014-01-03 CN CN201910000819.0A patent/CN110106229B/zh active Active
- 2014-01-03 EP EP14735397.3A patent/EP2941629B1/en active Active
- 2014-01-03 AU AU2014203987A patent/AU2014203987B2/en active Active
- 2014-01-03 WO PCT/US2014/010173 patent/WO2014107571A1/en not_active Ceased
- 2014-01-03 US US14/759,238 patent/US20150353920A1/en not_active Abandoned
- 2014-01-03 EP EP18199291.8A patent/EP3499212B1/en active Active
- 2014-01-03 CN CN201480002901.2A patent/CN105026911B/zh active Active
- 2014-01-03 BR BR112015016136A patent/BR112015016136A2/pt not_active IP Right Cessation
- 2014-01-03 CA CA2897207A patent/CA2897207C/en active Active
- 2014-01-03 JP JP2015551774A patent/JP6449781B2/ja active Active
- 2014-01-03 MX MX2015008727A patent/MX366153B/es active IP Right Grant
-
2015
- 2015-07-05 IL IL239786A patent/IL239786B/en active IP Right Grant
-
2018
- 2018-04-20 AU AU2018202789A patent/AU2018202789B2/en active Active
-
2019
- 2019-06-19 IL IL267526A patent/IL267526B/en active IP Right Grant
-
2020
- 2020-06-05 US US16/893,966 patent/US20210171934A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP2941629A4 (en) | 2017-03-22 |
| IL267526B (en) | 2020-10-29 |
| BR112015016136A2 (pt) | 2017-07-11 |
| EP2941629A1 (en) | 2015-11-11 |
| JP2016502862A (ja) | 2016-02-01 |
| MX2019007742A (es) | 2019-08-29 |
| CA2897207C (en) | 2022-08-02 |
| AU2018202789A1 (en) | 2018-05-10 |
| IL267526A (en) | 2019-08-29 |
| MX2015008727A (es) | 2016-04-21 |
| CA2897207A1 (en) | 2014-07-10 |
| EP3499212A1 (en) | 2019-06-19 |
| AU2014203987A1 (en) | 2015-08-20 |
| HK1217365A1 (en) | 2017-01-06 |
| EP2941629B1 (en) | 2018-10-10 |
| CN110106229A (zh) | 2019-08-09 |
| AU2018202789B2 (en) | 2020-01-02 |
| MX366153B (es) | 2019-06-28 |
| IL239786A0 (en) | 2015-08-31 |
| EP3499212B1 (en) | 2020-08-12 |
| IL239786B (en) | 2019-07-31 |
| CN105026911A (zh) | 2015-11-04 |
| US20210171934A1 (en) | 2021-06-10 |
| CN110106229B (zh) | 2023-03-28 |
| AU2014203987B2 (en) | 2018-01-25 |
| CN105026911B (zh) | 2019-01-22 |
| US20150353920A1 (en) | 2015-12-10 |
| MX392552B (es) | 2025-03-11 |
| WO2014107571A1 (en) | 2014-07-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6449781B2 (ja) | 微細小胞の単離方法 | |
| JP7128866B2 (ja) | 微小小胞体を単離する方法、および生体試料から核酸を抽出する方法 | |
| US20210238582A1 (en) | Automated and manual methods for isolation of extracellular vesicles and co-isolation of cell-free dna from biofluids | |
| US11268085B2 (en) | Methods for isolating microvesicles and extracting nucleic acids from biological samples | |
| HK40009837A (en) | Methods for isolating microvesicles | |
| HK1217365B (en) | Methods for isolating microvesicles | |
| HK1238676A1 (en) | Methods for isolating microvesicles and extracting nucleic acids from biological samples |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20161102 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20170929 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20171031 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20180129 |
|
| A524 | Written submission of copy of amendment under article 19 pct |
Free format text: JAPANESE INTERMEDIATE CODE: A524 Effective date: 20180424 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20180807 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20181016 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20181106 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20181206 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6449781 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |